

DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
CENTERS FOR DISEASE CONTROL

MINUTES OF MEETING

Immunization Practices Advisory Committee
April 5-6, 1984
Atlanta, Georgia

The Immunization Practices Advisory Committee (ACIP) met in Room 207 at the Centers for Disease Control, Atlanta, Georgia, on April 5-6, 1984. Those in attendance are listed below:

COMMITTEE MEMBERS PRESENT

Dr. James Chin, Chairman
Dr. Ellen S. Alkon
Dr. Anne A. Gershon
Dr. Samuel L. Katz
Dr. Joan K. Leavitt
Dr. Edward A. Mortimer
Dr. Frederick L. Ruben
Dr. William Schaffner II
Dr. Stephen C. Schoenbaum

Ex Officio Members

Dr. W. S. Jordan, Jr. (NIH)
Dr. Harry Meyer, Jr. (FDA)
(represented by Dr. Elaine Esber)

Liaison Representatives

Dr. Philip A. Brunell (AAP)
Dr. J. Michael Dixon (NACI)
Dr. Janice Hutchinson (ACP)
(represented by Dr. N. P. Raposa)

Executive Secretary

Dr. Jeffrey P. Koplan

COMMITTEE MEMBERS ABSENT

Dr. D. A. Henderson

Liaison Representatives Absent

Capt. Peter A. Flynn
Dr. Theodore Eickhoff

INVITED PARTICIPANTS

Dr. Leonard E. Safon
Dr. Cladd E. Stevens
Dr. Arlene McLean
Dr. David Fedson

HHS STAFF PRESENT

FOOD AND DRUG ADMINISTRATION

Center for Drugs and Biologics

Dr. Elaine Esber
Dr. Carolyn Hardegree
Dr. Gerald Quinnan
Dr. Robert Gerety

HEALTH RESOURCES AND SERVICES ADMINISTRATION

Bureau of Health Care Delivery and

Assistance

Dr. Allan Noonan

CENTERS FOR DISEASE CONTROL

Office of the Director

Dr. Gary Noble
Mr. Mike Kerr
Mr. Robert Alden
Ms. Karen Kaunitz
Ms. Verla Neslund

Center for Infectious Diseases

Dr. Walter R. Dowdle
Dr. Claire Broome
Dr. John Bennett
Dr. F. A. Murphy
Dr. William Winkler
Dr. Alan Kendal
Dr. Mark Kane
Dr. Kenneth Bernard
Dr. Kenneth Herrmann
Dr. Gary Schatz
Dr. Stephen Cochi
Ms. Julia Garner
Dr. Gail Bolen

CENTERS FOR DISEASE CONTROL (continued)

Center for Prevention Services

Dr. Alan Hinman
Dr. Walter Orenstein
Dr. Stephen Preblud
Dr. Kenneth Bart

International Health Program Office
Dr. Myron G. Schultz

OTHERS PRESENT

Dr. H. Bruce Dull
Mr. Douglas B. Reynolds
Dr. Eva Lydick
Dr. Victor A. Jegede
Ms. Karlyn L. Shedlowski
Dr. Steffen Gruhn
Dr. Gary J. Bridi
Dr. Saul Krugman
Dr. Richard F. White
Dr. Alan H. Goldscheim
Mr. Charles S. Taylor
Dr. Raymond W. Tiedemann
LTC James W. Kirkpatrick
Col. Robert G. Self
Mr. J. A. Morris
Dr. Paul Hung
Ms. Myra Adamthwaite
Dr. Stephen Weiss
Ms. Jane Sisk

The meeting was opened at 8:30 a.m. on April 5, 1984, by the Chairman Dr. James Chin who welcomed members of the Committee. Dr. Norbert Rapoza represented the AMA for Dr. Janice Hutchinson, and Dr. Elaine Esber represented the FDA for Dr. Harry Meyer. Drs. Henderson, Eickhoff, and Flynn were unable to attend.

Mr. William C. Watson presented letters and certificates from the Director of CDC to Drs. Stephen C. Schoenbaum and Frederick L. Ruben in appreciation of their assistance and advice as members of the Committee from July 1980 to June 1984. In addition, Mr. Watson presented to each an autographed copy of Princes and Peasants: Smallpox in History by Donald R. Hopkins, on behalf of the Committee.

PNEUMOCOCCAL POLYSACCHARIDE VACCINE

Drs. Gail Bolan and Claire Broome, Division of Bacterial Diseases, CID, led the discussion of an updated draft containing new data on the pneumococcal polysaccharide vaccine and revised recommendations regarding its use. The draft statement had been mailed to Committee members for their review prior to the meeting. A 14-valent polysaccharide vaccine against disease caused by Streptococcus pneumoniae (pneumococcus) licensed in the United States in 1977 has been replaced by a 23-valent polysaccharide vaccine licensed in 1983. The Committee discussed the statement and Dr. Chin appointed a subcommittee consisting of Drs. Schaffner, Schoenbaum, and Gershon to make specific changes to present to the Committee the following day.

The Committee continued discussion of the pneumococcal statement at 9 a.m. on April 6. Dr. Broome distributed a revised draft statement which included suggestions from the previous day's discussion. Dr. Schoenbaum, member of the subcommittee, read several sections of the revised draft, noting that some sections had been expanded such as recommendations for vaccine use, and strategies for vaccine delivery.

Dr. Chin asked the Committee to review the draft for editorial and content changes and send their suggestions to Dr. Koplan within a few days.

HAEMOPHILUS INFLUENZAE

The Committee briefly discussed Haemophilus influenzae. There may be a licensed product before the next ACIP meeting in September. Dr. Chin appointed a subcommittee consisting of Drs. Katz, Mortimer, and Leavitt to work with the CDC staff in preparing a draft statement for H. influenzae vaccine use.

RABIES

Dr. Ken Bernard, Division of Viral Diseases, CID, presented data on immune complex-type hypersensitivity reactions in persons receiving human diploid cell rabies vaccine (HDCV) for booster immunization. Dr. Winkler, Division of Viral Diseases, CID, presented data on intradermal and intramuscular responses and discussed rabies immunization regimens, pre-exposure rabies prophylaxis for persons with special risks and boosters for high-risk groups. Dr. Chin asked Dr. Winkler to use comments given during the Committee's discussion and prepare a table on criteria for vaccine use to present to the Committee the next day.

The Committee discussed the content of a telegram from CDC to State health officials regarding allergic reactions following booster doses of human rabies vaccine, which include hives, swelling of the joints, rash, and sometimes facial swelling (angioneurotic edema).

The Committee continued discussion of rabies at 8 a.m. on April 6. A revised draft table was distributed and discussion followed on a report "Systemic Allergic Reactions Following Immunization with HDCV." The criteria for vaccine use for pre-exposure regimens were further discussed. Dr. Chin asked the Committee to review the draft and forward their comments to Dr. Koplan within 2 weeks.

INFLUENZA

Dr. Kendal led a discussion on the draft statement which had been mailed to the Committee for their review before the meeting.

On day 2 the influenza draft was again reviewed. A section on "Vaccine Administration and Strategies" was added. The Committee was asked to give their comments on the influenza statement to Dr. Kendal that day, or to call or send them early the following week to Dr. Koplan. A representative from Connaught Laboratories stated vaccine production may be hindered by lack of egg availability and also the Cost may be increased next season.

HEPATITIS B

Dr. Kane, Division of Viral Diseases, reviewed the revised draft statement on post-exposure prophylaxis of hepatitis B. He discussed the cost effectiveness of hepatitis B antigen screening of pregnant women.

Dr. Cladd Stevens, New York Blood Center, presented data from recent studies on hepatitis B vaccine use.

OTHER BUSINESS

Dr. Hinman stated that the "Adult Immunization" statement had been delayed because of the recent revisions of several ACIP vaccine recommendations. He will use the influenza, pneumococcal, and hepatitis B statements revisions and incorporate the changes in the Adult Immunization statement prior to publishing it. However, the hepatitis B statement for international travel had not been fully discussed, and page 58 from the Adult Immunization draft statement was distributed (regarding hepatitis B). Further discussion was held regarding hepatitis B in international travelers. Drs. Kane and Hadler stated that U.S. citizens who will live in endemic areas may be at risk for hepatitis B.

Dr. Hinman led a discussion on recent outbreaks of measles in junior high schools in the United States. Outbreaks on campuses are difficult to control because students could not be identified. Few campuses require or systematically record documentation of immunity. Measles in young adults may be difficult to identify because physicians who treat this group may not consider measles as a likely diagnosis.

The National Immunization Conference, sponsored by the Centers for Disease Control, will be held May 21-24, 1984, at the Marriott Hotel, Boston, Massachusetts.

FUTURE ACIP MEETING DATES

The next Committee meeting was scheduled for September 10-11, 1984. Agenda items will include:

- Haemophilus influenzae
- Hepatitis A and hepatitis B
- Review of OPV and IPV - update
- Japanese B encephalitis vaccine - update
- Varicella-Zoster Immune Globulin
- Update on status of legislation on vaccine compensation.

With the thanks of the Chairman, the meeting was adjourned at 12:30 p.m.

I hereby certify that, to the best of my knowledge, the foregoing summary of minutes is accurate and complete.

James Chin
James Chin, M.D.

May 8, 1984
Date